drugset / Trial / NCT03936192
A Parallel-group Active Comparator, Double-blind, Multicenter, Randomized, Double-blind, Phase III Clinical Study
RandomizedParallel-groupDouble-blindTreatment
Summary
A multicenter, randomized, double-blind, parallel-group, placebo-controlled, and active-drug, 12-week, multicenter clinical study. Participants will be randomized 2: 2: 1 to receive the combination of glucosamine sulfate + meloxicam (experimental group), combination of glucosamine sulfate + chondroitin sulfate (active control group) or placebo.
Timeline
- Start
- 2019-01
- Primary completion
- 2021-02
- Completion
- 2021-02
Outcome
Outcome not reported
Stopped: “Company decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Chondroitin | Unknown | 1200 mg | — |
| Subject | Meloxicam | Small molecule | 15 mg | — |
| Background | Glucosamine | Small molecule | 1500 mg | — |